Business Review, Development and Performance
The Company was admitted to trading on the Aquis Stock Exchange (‘AQSE’), formerly NEX Exchange Growth Market on 4 July 2018 as an investment vehicle to invest in the developing market for medicinal or therapeutic cannabis. Initially, the Company’s strategy was focused specifically on companies, projects or products in Israel, Canada and the Netherlands, although this strategy was broadened in September 2018 to permit investment in any jurisdiction which has well established laws in relation to medicinal cannabis.
Since the Company was listed in 2018, the directors have pursued their primary objective of creating long term value for Shareholders through the acquisition of strategic stakes in companies in the medicinal cannabis sector which the directors believe have potential for substantial growth. The current investments are:
- a shareholding of 0.90% in iCAN Israel-Cannabis Limited (‘iCAN’), an international cannabis conference platform and cannabis company incubator and advisor. In the year under review, iCAN has expanded its conference platform and increased the number of companies in its incubator group. Since the end of the reporting period, iCAN has transitioned to an online offering to maintain revenue streams during the COVID-19 pandemic. Also, since the end of the period, Ananda converted its convertible debt into additional equity in iCAN.
- 15% interest in Liberty Herbal Technologies Limited (‘LHT’), the 100 per cent owner and developer of hapac®, ready to use sachets of pre-ground dried herbs for portable vaporisers. During the period under review, LHT continued to sell its hap® devices and sachets in Italy. It has also commenced a range of discussions regarding potential collaborations to expand the footprint of the company.
- 50% (via 100% owned Tiamat Agriculture and 50% owned DJT Group Limited) interest in DJT Plants Limited, which has applied to the Home Office of the UK government for a licence to grow medicinal cannabis first for research. Its ultimate objective is to grow medicinal cannabis in the UK for commercial purposes. Subsequent to the end of the period under review the licence was granted.
The Company is very much in its early stages with its investments not yet generating any revenue. The Company has had no revenue for the year and incurred a loss of £495,109.
Statement of Comprehensive Income
|31 Jan 2021||31 Jan 2020|
|Loss from operations||(495,996)||(366,168)|
|Other Comprehensive Income|
|Foreign Exchange Translation Gain/(Loss)||887||(8,292)|
|Total comprehensive loss for the year||(495,109)||(374,460)|
Statement of Financial Position
|31 Jan 2021||31 Jan 2020|
|Trade and other receivables||12,718||56,499|
|Total current assets||12,718||132,377|
|Trade and other payables||462,299||191,742|
|Net current assets||(449,581)||(59,365)|
|Total assets less current liabilities||831,037||1,228,397|
|Capital and reserves|
|Share options reserve||447,337||441,755|
|Total equity and liabilities||831,037||1,228,397|
The financial statements were approved and authorised for issue by the Board and were signed on its behalf by:
5 July 2021
The Directors of the Company accept responsibility for the contents of this announcement.
|ANANDA DEVELOPMENTS PLC
Chief Executive Officer
|+44 (0)7463 686 497
|PETERHOUSE CAPITAL LIMITED
|+44 (0)20 7469 0930|